Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.30 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10451868 | 0.83 | ITGB1 (0.36) | FOLH1NAALAD2GABRR1CYP1A2 | |
| SCHEMBL3901087 | 0.83 | ITGB1 (0.36) | FOLH1NAALAD2GABRR1CYP1A2 | |
| SCHEMBL93072 | 0.83 | FOLH1 (0.35) | FOLH1NAALAD2GABRR1CYP1A2 | |
| SCHEMBL813214 | 0.83 | ITGB1 (0.36) | FOLH1NAALAD2GABRR1CYP1A2 | |
| SCHEMBL6000457 | 0.79 | GRIK1 (0.38) | — | |
| SCHEMBL3898740 | 0.79 | KDM4E (0.33) | — | |
| SCHEMBL7559349 | 0.79 | GRIK1 (0.38) | — | |
| SCHEMBL9813168 | 0.79 | CA1 (0.44) | — | |
| SCHEMBL28889731 | 0.77 | — | — | |
| SCHEMBL4594766 | 0.76 | CYP2C9 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| EP-1571165-B1 | Compositions for the preparation of hydrophobic coatings | TOFFANO LORENZO (IT) | 2009-01-07 | — | — | EP | disclosed |
| EP-1571165-A1 | Compositions for the preparation of hydrophobic coatings | Toffano, Lorenzo (IT) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | FOLH1 486/4885NAALAD2 473/4885GABRR1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.